

# Comparison of different shock wave therapies in the treatment of erectile dysfunction

<b>Submission date</b> 10/10/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 10/10/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/10/2025	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Erectile dysfunction (ED) is the inability to get or keep an erection firm enough for sexual activity. It is a common condition, affecting up to half of men aged between 40 and 70 years. One of the newer treatments for ED uses shock waves called shockwave therapy to improve blood flow in the penis. There are two main types of this treatment: focused shockwave therapy (fSWT) and radial wave therapy (rWT). Both are believed to stimulate the growth of new blood vessels and improve tissue health. The aim of this study is to compare the long-term effectiveness of these two methods in improving erectile function in men with blood vessel related ED.

### Who can participate?

Men aged 40 to 70 years who have had erectile dysfunction for at least 3 months and have a moderate to severe reduction in erectile function

### What does the study involve?

This was a two-centre prospective cohort study, meaning men were treated and followed over time in two different hospitals. One group received focused shockwave therapy (fSWT) using a device called ED1000, and the other group received radial wave therapy (rWT) using a Zimmer enPuls Pro device. Both treatments involved a series of short, painless sessions over several weeks. No anaesthesia or medication was required. Participants completed questionnaires on erectile function before treatment, after 3 months, and again after 1 year.

### What are the possible benefits and risks of participating?

The possible benefit is improved erectile function and better sexual performance without the need for medication or surgery.

The treatment is considered safe and non-invasive, with no reported serious side effects. Some men might experience mild temporary discomfort during treatment, but no long-term risks are expected.

### Where is the study run from?

1. Göksel Bayar Special Healthcare Company (Turkiye)
2. Ismail Basmaci Special Healthcare Company (Turkiye)

When is the study starting and how long is it expected to run for?  
June 2021 to July 2024

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
Assoc. Prof. Göksel Bayar, goxelle@gmail.com, goksel.bayar@medicalpark.com.tr

## Contact information

**Type(s)**  
Public, Scientific, Principal investigator

**Contact name**  
Dr Göksel Bayar

**Contact details**  
Guzeller Mah Kavak Cad Medical Park Hastanesi  
Gebze  
Türkiye  
41400  
+90 (0)5315849749  
goksel.bayar@medicalpark.com.tr

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**ClinicalTrials.gov (NCT)**  
Nil known

**Protocol serial number**  
20131113

## Study information

**Scientific Title**  
Comparative effectiveness of focused shockwave therapy and radial wave therapy for erectile dysfunction: a two-centre prospective cohort study

**Study objectives**  
To evaluate the efficacy of focused and non-focused shock wave treatment of erectile dysfunction for at least 1 year.

**Ethics approval required**  
Ethics approval required

**Ethics approval(s)**

approved 01/06/2023, Samsun University Local Ethics Committee (İstiklal Mahallesi Tekel Cad, Balıca Kampüsü No:2, 19 Mayıs, Samsun, 55000, Türkiye; +90 (0)3623130055; samsununu.kaek@gmail.com), ref: 20231224

**Study design**

Non-randomized study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Erectile dysfunction

**Interventions**

This was a two-centre prospective cohort study, meaning men were treated and followed over time in two different hospitals. One group received focused shockwave therapy (fSWT) using a device called ED1000, and the other group received radial wave therapy (rWT) using a Zimmer enPuls Pro device. Both treatments involved a series of short, painless sessions over several weeks. No anaesthesia or medication was required. Participants completed questionnaires on erectile function before treatment, after 3 months, and again after 1 year. Chi-square and Student's t-tests will be used for statistical comparison. The Wilson test will be used to assess the effectiveness of the treatments themselves.

**Intervention Type**

Device

**Phase**

Phase IV

**Drug/device/biological/vaccine name(s)**

Shock wave treatment

**Primary outcome(s)**

Erectile function measured using the International Index of Erectile Function (IIEF) score before treatment, after 3 months, and after 1 year

**Key secondary outcome(s)**

Sexual function assessed using the Sexual Encounter Profile (SEP) before treatment, after 3 months, and after 1 year

**Completion date**

01/07/2024

**Eligibility****Key inclusion criteria**

Erectile dysfunction patients with vascular insufficiency

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

30 years

**Upper age limit**

70 years

**Sex**

Male

**Total final enrolment**

200

**Key exclusion criteria**

1. Pelvic surgery, e.g. radical prostatectomy
2. Radiotherapy
3. Neuropathic illness

**Date of first enrolment**

01/07/2023

**Date of final enrolment**

01/07/2024

## **Locations**

**Countries of recruitment**

Türkiye

**Study participating centre**

**Göksel Bayar Special Healthcare Company**

Guzeller Mah Kavak Cad Medical Park Hastanesi

Gebze

Türkiye

41400

**Study participating centre**

**Ismail Basmaci Special Healthcare Company**  
Artuklu Mah  
Mardin  
Türkiye  
47060

## **Sponsor information**

**Organisation**  
Göksel Bayar Special Healthcare Company

## **Funder(s)**

**Funder type**  
Other

**Funder Name**  
Investigator initiated and funded

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date

### **IPD sharing plan summary**

Data sharing statement to be made available at a later date